BLA 761460 · Abbvie INC
Decnupaz
Pivekimab Sunirine-Pvzy · Single-Dose
NovelPriority reviewOrphanCDER novel approval, May 27, 2026: To treat adults with blastic plasmacytoid dendritic cell neoplasm
Last checked: Nov 20, 2026Latest source record: May 27, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2026
May 27, 2026
Approved uses
1
Original approval plus efficacy supplements
Registered trials
3
1 Phase 3, 2 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: HEPATOTOXICITY, INCLUDING HEPATIC VENO-OCCLUSIVE DISEASE (VOD) (ALSO KNOWN AS SINUSOIDAL OBSTRUCTION SYNDROME) DECNUPAZ can cause hepatotoxicity, including severe or fatal hepatic VOD (also known as sinusoidal obstruction syndrome) [see Warnings and Precautions ( 5.1 )] . Closely monitor patients for signs and symptoms of VOD including elevations in liver tests, hepatomegaly (which may be painful), rapid weight gain, and ascites [see Warnings and Precautions ( 5.1 )] . Monitor liver tests, including ALT, AST, and total bilirubin, prior to each dose of DECNUPAZ [see Warnings and Precautions ( 5.1 )] . Delay DECNUPAZ dosage for liver test elevation. Permanently discontinue DECNUPAZ for patients who experience VOD [see Dosage and Administration ( 2.4 ) and Warnings and Precautions ( 5.1 )] . WARNING: HEPATOTOXICITY, INCLUDING HEPATIC VENO-OCCLUSIVE DISEASE (VOD) (ALSO KNOWN AS...
What it is approved for
From the label in effect May 27, 2026.
1. INDICATIONS AND USAGE DECNUPAZ is indicated for the treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). DECNUPAZ is a CD123-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). ( 1 )
Mechanism: Pivekimab sunirine-pvzy is a CD123 (alpha-subunit of the interleukin-3 receptor)-directed antibody-drug conjugate (ADC). The antibody is a humanized anti-CD123 IgG1. Pivekimab sunirine-pvzy binds to CD123 expressing cells and upon intracellular processing releases a cell membrane-permeable payload, FGN849, leading to DNA alkylation, single-strand DNA breaks, apoptosis, and cell death. The payload, FGN849, is a member of the indolinobenzodiazepine pseudodimer (IGN) class of cytotoxic molecules. Pivekimab sunirine-pvzy exhibited antitumor activity in in vitro and in vivo models of BPDCN.
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 27, 2026 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLetterLabelReview
1 products under this application
- DECNUPAZ · PIVEKIMAB SUNIRINE-PVZY 2MG · VIAL, SINGLE-DOSE · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Pivekimab Sunirine" as an intervention, any sponsor and status, largest first.
AbbVieAbbVie (ABBV)
NCT07581002 · 660 participants (planned) · Start Jun 30, 2026 · Primary completion Jun 2032
Drug: Pivekimab Sunirine; Venetoclax and 2 more · For: Acute Myeloid Leukemia
Sites: Duarte, California; Tampa, Florida; Atlanta, Georgia · 40 sites in all
- Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid NeoplasmsActive, not recruiting
Fred Hutchinson Cancer CenterAcademic, hospital or other
NCT06034470 · 30 participants · Start Dec 18, 2023 · Primary completion May 31, 2026
Drug: Cytarabine; Fludarabine and 3 more · For: Acute Myeloid Leukemia; Mixed Phenotype Acute Leukemia; Myelodysplastic Syndrome and 2 more
Sites: Seattle, Washington
AbbVieAbbVie (ABBV)
NCT07306832 · 18 participants (planned) · Start May 20, 2026 · Primary completion Apr 2028
Drug: Pivekimab Sunirine · For: Acute Myeloid Leukemia
Sites: Palo Alto, California; Atlanta, Georgia; Valhalla, New York · 14 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study.
Daver NG, Montesinos P, DeAngelo DJ, et al. · Lancet Oncol 2024 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm.
Pemmaraju N, Marconi G, Montesinos P, et al. · J Clin Oncol 2026 · Multicenter Study, Clinical Trial, Phase II
Sponsor: AbbVie
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.